These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38476099)

  • 1. Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.
    Hershey AD; Paiva da Silva Lima G; Pannacciulli N; Mackowski M; Koukakis R; McVige JW
    Clin Transl Sci; 2024 Mar; 17(3):e13755. PubMed ID: 38476099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
    Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
    Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
    Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
    Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.
    Ashina M; Goadsby PJ; Reuter U; Silberstein S; Dodick D; Rippon GA; Klatt J; Xue F; Chia V; Zhang F; Cheng S; Mikol DD
    Cephalalgia; 2019 Oct; 39(11):1455-1464. PubMed ID: 31146544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
    Lampl C; Kraus V; Lehner K; Loop B; Chehrenama M; Maczynska Z; Ritter S; Klatt J; Snellman J
    J Headache Pain; 2022 Aug; 23(1):104. PubMed ID: 35978286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
    Tepper S; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein S; Winner P; Leonardi D; Mikol D; Lenz R
    Lancet Neurol; 2017 Jun; 16(6):425-434. PubMed ID: 28460892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
    Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
    Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
    Hirata K; Takeshima T; Sakai F; Numachi Y; Yoshida R; Koukakis R; Hasebe M; Yui D; da Silva Lima GP; Cheng S
    BMJ Open; 2023 Aug; 13(8):e068616. PubMed ID: 37597868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials.
    Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G
    JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
    Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
    J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
    Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
    BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a
    Lipton RB; Tepper SJ; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Zhang F; Rippon GA; Cheng S; Mikol DD
    Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of erenumab in migraine prevention: evidences from direct and indirect comparisons.
    Wang X; He Q; Wen D; Ma L; You C
    Neurol Sci; 2022 Apr; 43(4):2751-2758. PubMed ID: 34731334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
    Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
    Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
    Schenk H; Holle D; Nsaka M; Kleinschnitz C; Glas M; Scheffler A
    J Headache Pain; 2022 May; 23(1):55. PubMed ID: 35538414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine.
    de Hoon J; Van Hecken A; Vandermeulen C; Yan L; Smith B; Chen JS; Bautista E; Hamilton L; Waksman J; Vu T; Vargas G
    Clin Pharmacol Ther; 2018 May; 103(5):815-825. PubMed ID: 28736918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.